Monitor for the actual execution of this sale on Form 4. A completed sale by a director/officer of this size (approx. $2M) could signal a modest overhang, but the stock's strong recent performance and high institutional ownership suggest limited downside. Watch for any subsequent insider buying or changes in company guidance.
MIRM drugs
MIRM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $98.23entry
- T+1 · 3mo ago +0.75%α +0.50% · $98.97
- T+5 · 3mo ago +2.69%α +3.09% · $100.87
- T+20 · 2mo ago +0.07%α +1.13% · $98.30
- T+60 · 13d ago −1.28%α −0.80% · $96.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of intent to sell 20,000 shares of common stock, with an estimated aggregate market value of approximately $1,978,346. This filing signals a planned sale by a key insider, though it is an advance notice of intent and the sale may not be executed. The filing provides no details on the reason for the sale, but the timing and insider status warrant attention.
Key Facts
- Christopher Peetz (officer and director) filed a Form 144 to sell 20,000 shares of common stock.
- Estimated aggregate market value of the proposed sale is approximately $1,978,346.
- The filing date is August 10, 2026, and the sale is intended to be executed on the same date.
- The shares to be sold are from a stock option exercise on August 10, 2026.
- Peetz has not sold any other securities in the past 3 months.
Financial Impact
Proposed sale of 20,000 shares valued at approximately $1.98 million.
Risk Factors
- Insider sale may signal lack of confidence or personal liquidity needs.
- Sale of 20,000 shares could represent a meaningful portion of Peetz's holdings, though exact percentage is not disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-007862 |
| Document: 0001950047-26-007862-index.html | 0001950047-26-007862 |
| Document: 0001950047-26-007862.txt | 0001950047-26-007862 |
Track record
27 reports on MIRM
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers